187 results on '"Witcher, Michael"'
Search Results
2. Supplementary Data from MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ
3. Data from MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ
4. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles
5. Achieving clinical success with BET inhibitors as anti-cancer agents
6. Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming
7. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer
8. MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors
9. Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism
10. Oncogenic activity of poly (ADP-ribose) glycohydrolase
11. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
12. Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma
13. Tables S1, S2, S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
14. Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
15. Supplementary Figure Legends and Materials and Methods from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
16. Table S4 from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
17. Figure S4 from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
18. Data from MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ
19. Data from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
20. Supplementary Figure Legends and Table S1, S2, S3 from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
21. Supplementary Data from MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ
22. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential
23. Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I
24. 3D chromatin remodeling potentiates transcriptional programs driving cell invasion
25. Single base-pair resolution analysis of DNA binding motif with MoMotif reveals an oncogenic function of CTCF zinc-finger 1 mutation
26. Abstract 131: The role of p66ShcA in the melanoma oncogenesis process
27. Histone Lysine Demethylase JARID1a Activates CLOCK-BMAL1 and Influences the Circadian Clock
28. POGZ promotes homology‐directed DNA repair in an HP1‐dependent manner
29. 3D Chromatin Remodeling Potentiates Transcriptional Programs Driving Cell Invasion
30. POGZ modulates the DNA damage response in a HP1-dependent manner
31. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines
32. p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors
33. Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
34. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
35. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines
36. POGZ promotes homology‐directed DNA repair in an HP1‐dependent manner.
37. Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter
38. Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells
39. Abstract NT-118: SEQUENTIAL THERAPEUTIC TARGETING OF OVARIAN CANCER HARBORING DYSFUNCTIONAL BRCA1
40. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?
41. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
42. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ
43. Oncogenic activity of poly (ADP-ribose) glycohydrolase
44. HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site
45. Abstract LB-231: Genomic profiling in serial metastatic colorectal tumors identifies copy number alterations and spatio temporal intra-patient heterogeneity profiles associated with clinical response. Q-CROC-01: NCT00984048
46. WITHDRAWN: Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential
47. Epigenetic Silencing of the p16INK4a Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin Boundary
48. Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide
49. Abstract 2795: Integrating multiomics discovery approaches to identify biomarkers of therapeutic resistance in metastatic colorectal cancer through analyses of multiple sequential tumor and liquid biopsies; Qcroc01: NCT00984048
50. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.